| 1. |
- Borisov, S, et al.
(författare)
-
Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report
- 2019
-
Ingår i: The European respiratory journal. - : European Respiratory Society (ERS). - 1399-3003 .- 0903-1936. ; 54:6
-
Tidskriftsartikel (refereegranskat)abstract
- The World Health Organization (WHO) recommends that countries implement pharmacovigilance and collect information on active drug safety monitoring (aDSM) and management of adverse events.The aim of this prospective study was to evaluate the frequency and severity of adverse events to anti-tuberculosis (TB) drugs in a cohort of consecutive TB patients treated with new (i.e. bedaquiline, delamanid) and repurposed (i.e. clofazimine, linezolid) drugs, based on the WHO aDSM project. Adverse events were collected prospectively after attribution to a specific drug together with demographic, bacteriological, radiological and clinical information at diagnosis and during therapy. This interim analysis included patients who completed or were still on treatment at time of data collection.Globally, 45 centres from 26 countries/regions reported 658 patients (68.7% male, 4.4% HIV co-infected) treated as follows: 87.7% with bedaquiline, 18.4% with delamanid (6.1% with both), 81.5% with linezolid and 32.4% with clofazimine. Overall, 504 adverse event episodes were reported: 447 (88.7%) were classified as minor (grade 1–2) and 57 (11.3%) as serious (grade 3–5). The majority of the 57 serious adverse events reported by 55 patients (51 out of 57, 89.5%) ultimately resolved. Among patients reporting serious adverse events, some drugs held responsible were discontinued: bedaquiline in 0.35% (two out of 577), delamanid in 0.8% (one out of 121), linezolid in 1.9% (10 out of 536) and clofazimine in 1.4% (three out of 213) of patients. Serious adverse events were reported in 6.9% (nine out of 131) of patients treated with amikacin, 0.4% (one out of 221) with ethionamide/prothionamide, 2.8% (15 out of 536) with linezolid and 1.8% (eight out of 498) with cycloserine/terizidone.The aDSM study provided valuable information, but implementation needs scaling-up to support patient-centred care.
|
|
| 2. |
- Martucci, M., et al.
(författare)
-
Analysis on H spectral shape during the early 2012 SEPs with the PAMELA experiment
- 2014
-
Ingår i: Nuclear Instruments and Methods in Physics Research Section A. - : Elsevier BV. - 0168-9002 .- 1872-9576. ; 742, s. 158-161
-
Tidskriftsartikel (refereegranskat)abstract
- The satellite-borne PAMELA experiment has been continuously collecting data since 2006. This apparatus is designed to study charged particles in the cosmic radiation. The combination of a permanent magnet, a silicon strip tracker and a silicon-tungsten imaging calorimeter, and the redundancy of instrumentation allow very precise studies on the physics of cosmic rays in a wide energy range and with high statistics. This makes PAMELA a very suitable instrument for Solar Energetic Particle (SEP) observations. Not only does it span the energy range between the ground-based neutron monitor data and the observations of SEPs from space, but PAMELA also carries out the first direct measurements of the composition for the highest energy SEP events, including those causing Ground Level Enhancements (GLEs). In particular, PAMELA has registered many SEP events during solar cycle 24, offering unique opportunities to address the question of high-energy SEP origin. A preliminary analysis on proton spectra behaviour during this event is presented in this work.
|
|
| 3. |
- Ricci, M., et al.
(författare)
-
Study on 2012 march 7 solar particle event and forbush decrease with the PAMELA experiment
- 2013
-
Ingår i: Proceedings of the 33rd International Cosmic Rays Conference, ICRC 2013. - : Sociedade Brasileira de Fisica. - 9788589064293
-
Konferensbidrag (refereegranskat)abstract
- The PAMELA (Payload for Antimatter Matter Exploration and Light-nuclei Astro-physics) space-borne experiment was launched on 15 June 2006 and has been continuously collecting data since then. The apparatus measures electrons, positrons, protons, anti-protons and heavier nuclei from about 100 MeV to several hundreds of GeV. The on-board instrumentation is built around a permanent magnet with a silicon microstrip tracker, providing charge and track detection information. During solar maximum conditions of solar cycle 24, PAMELA has been providing key information about solar energetic particles (SEPs) and their influence at Earth. We discuss here the recent 2012 March 7 SEP event with a brief comment on the subsequent Forbush decrease, registered by PAMELA. This event was also observed by Fermi/LAT exhibiting unprecedented time-extended γ-ray emission (> 100 MeV) lasting nearly 20 hours. We compare the derived accelerated ion population at the Sun with the ion population measured in space by PAMELA and discuss the implications for particle acceleration.
|
|
| 4. |
|
|
| 5. |
|
|
| 6. |
- Adriani, O., et al.
(författare)
-
Design of an Antimatter Large Acceptance Detector In Orbit (ALADInO)
- 2022
-
Ingår i: Instruments. - : MDPI AG. - 2410-390X. ; 6:2
-
Tidskriftsartikel (refereegranskat)abstract
- A new generation magnetic spectrometer in space will open the opportunity to inves-tigate the frontiers in direct high-energy cosmic ray measurements and to precisely measure the amount of the rare antimatter component in cosmic rays beyond the reach of current missions. We propose the concept for an Antimatter Large Acceptance Detector In Orbit (ALADInO), designed to take over the legacy of direct measurements of cosmic rays in space performed by PAMELA and AMS-02. ALADInO features technological solutions conceived to overcome the current limi-tations of magnetic spectrometers in space with a layout that provides an acceptance larger than 10 m2 sr. A superconducting magnet coupled to precision tracking and time-of-flight systems can provide the required matter–antimatter separation capabilities and rigidity measurement resolution with a Maximum Detectable Rigidity better than 20 TV. The inner 3D-imaging deep calorimeter, designed to maximize the isotropic acceptance of particles, allows for the measurement of cosmic rays up to PeV energies with accurate energy resolution to precisely measure features in the cosmic ray spectra. The operations of ALADInO in the Sun–Earth L2 Lagrangian point for at least 5 years would enable unique revolutionary observations with groundbreaking discovery poten-tials in the field of astroparticle physics by precision measurements of electrons, positrons, and antiprotons up to 10 TeV and of nuclear cosmic rays up to PeV energies, and by the possible unam-biguous detection and measurement of low-energy antideuteron and antihelium components in cosmic rays.
|
|
| 7. |
|
|
| 8. |
|
|
| 9. |
- Getahun, H, et al.
(författare)
-
Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries
- 2015
-
Ingår i: The European respiratory journal. - : European Respiratory Society (ERS). - 1399-3003 .- 0903-1936. ; 46:6, s. 1563-1576
-
Tidskriftsartikel (refereegranskat)abstract
- Latent tuberculosis infection (LTBI) is characterised by the presence of immune responses to previously acquired Mycobacterium tuberculosis infection without clinical evidence of active tuberculosis (TB). Here we report evidence-based guidelines from the World Health Organization for a public health approach to the management of LTBI in high risk individuals in countries with high or middle upper income and TB incidence of <100 per 100 000 per year. The guidelines strongly recommend systematic testing and treatment of LTBI in people living with HIV, adult and child contacts of pulmonary TB cases, patients initiating anti-tumour necrosis factor treatment, patients receiving dialysis, patients preparing for organ or haematological transplantation, and patients with silicosis. In prisoners, healthcare workers, immigrants from high TB burden countries, homeless persons and illicit drug users, systematic testing and treatment of LTBI is conditionally recommended, according to TB epidemiology and resource availability. Either commercial interferon-gamma release assays or Mantoux tuberculin skin testing could be used to test for LTBI. Chest radiography should be performed before LTBI treatment to rule out active TB disease. Recommended treatment regimens for LTBI include: 6 or 9 month isoniazid; 12 week rifapentine plus isoniazid; 3–4 month isoniazid plus rifampicin; or 3–4 month rifampicin alone.
|
|
| 10. |
|
|
